Global Non-Hematological Cancers Market Will Almost Double to $141 Bn by 2021

Tuesday 10 May 2016, Amsterdam

Market Research Report Press Release The global treatment market for non-hematological cancers, which includes breast, colorectal, lung and prostate cancers, among others, will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, at a compound annual growth rate (CAGR) of 9.9%.

The company’s latest report* states that this robust growth will occur in spite of the patent expiries of a number of very commercially successful products, including Avastin, Erbitux and Herceptin. Avastin will see its first expiry in the EU in 2018, with the two others having already experienced EU expiries in 2014.

Adam Bradbury, Associate Analyst explains: “These drugs are all monoclonal Antibodies (mAbs), and are therefore expected to be less susceptible to market share and price erosion following patent expiry, due to practical and regulatory barriers to entry for biosimilars. In this way, these expirations will not pose too strong a barrier to growth.”

Market drivers will include the increasing prevalence of cancer globally, and the introduction of more targeted treatments, which will improve the overall survival of poor-performance-status patients and enable more rounds of chemotherapy to be administered.

There are 2,954 non-hematological oncology products in active development, 171 of which are in Phase III development or Pre-registration.

Bradbury explains: “Although none of the products in the late-stage pipeline are expected to reach the same levels of success as the highest revenue-generating drugs currently in the market, due to the competitiveness of the landscape, there are a number of candidates that are expected to achieve strong sales during the forecast period. These include AZD-4736 and neratinib, which are both forecast to generate blockbuster revenues by 2021.

“A range of companies are actively involved in the development or marketing of these new oncology products, including most of the top 20 pharmaceutical companies, smaller publicly traded companies and privately-held enterprises. In particular, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, and Novartis, are anticipated to maintain their strong market shares throughout the forecast period.

“While Roche’s market share within non-blood cancers is anticipated to decrease, partly due to the approaching patent expiries of Avastin and Tarceva, Roche is still expected to maintain the highest market share for non-hematological cancer treatment of any company throughout the forecast period.”

*Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

This report provides analysis of the global non-hematological cancers treatment space, specifically breast, colorectal, lung and prostate cancer. It features annualized market data from 2014 and forecast to 2021, as well as details on the current clinical and commercial landscape..

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News